Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement
- PMID: 31995682
- DOI: 10.1056/NEJMoa1910555
Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement
Abstract
Background: There are scant data on long-term clinical outcomes and bioprosthetic-valve function after transcatheter aortic-valve replacement (TAVR) as compared with surgical aortic-valve replacement in patients with severe aortic stenosis and intermediate surgical risk.
Methods: We enrolled 2032 intermediate-risk patients with severe, symptomatic aortic stenosis at 57 centers. Patients were stratified according to intended transfemoral or transthoracic access (76.3% and 23.7%, respectively) and were randomly assigned to undergo either TAVR or surgical replacement. Clinical, echocardiographic, and health-status outcomes were followed for 5 years. The primary end point was death from any cause or disabling stroke.
Results: At 5 years, there was no significant difference in the incidence of death from any cause or disabling stroke between the TAVR group and the surgery group (47.9% and 43.4%, respectively; hazard ratio, 1.09; 95% confidence interval [CI], 0.95 to 1.25; P = 0.21). Results were similar for the transfemoral-access cohort (44.5% and 42.0%, respectively; hazard ratio, 1.02; 95% CI, 0.87 to 1.20), but the incidence of death or disabling stroke was higher after TAVR than after surgery in the transthoracic-access cohort (59.3% vs. 48.3%; hazard ratio, 1.32; 95% CI, 1.02 to 1.71). At 5 years, more patients in the TAVR group than in the surgery group had at least mild paravalvular aortic regurgitation (33.3% vs. 6.3%). Repeat hospitalizations were more frequent after TAVR than after surgery (33.3% vs. 25.2%), as were aortic-valve reinterventions (3.2% vs. 0.8%). Improvement in health status at 5 years was similar for TAVR and surgery.
Conclusions: Among patients with aortic stenosis who were at intermediate surgical risk, there was no significant difference in the incidence of death or disabling stroke at 5 years after TAVR as compared with surgical aortic-valve replacement. (Funded by Edwards Lifesciences; PARTNER 2 ClinicalTrials.gov number, NCT01314313.).
Copyright © 2020 Massachusetts Medical Society.
Comment in
-
TAVR at 5 Years - Rematch or Swan Song for Surgery?N Engl J Med. 2020 Feb 27;382(9):867-868. doi: 10.1056/NEJMe2000240. N Engl J Med. 2020. PMID: 32101670 No abstract available.
-
Five-Year Outcomes with Transcatheter Aortic-Valve Replacement.N Engl J Med. 2020 Aug 6;383(6):594. doi: 10.1056/NEJMc2018853. N Engl J Med. 2020. PMID: 32757530 No abstract available.
-
Five-Year Outcomes with Transcatheter Aortic-Valve Replacement.N Engl J Med. 2020 Aug 6;383(6):594-595. doi: 10.1056/NEJMc2018853. N Engl J Med. 2020. PMID: 32757531 No abstract available.
-
Revalving to treat transcatheter valve failure.Lancet. 2023 Oct 28;402(10412):1500-1501. doi: 10.1016/S0140-6736(23)01735-X. Epub 2023 Aug 31. Lancet. 2023. PMID: 37660718 No abstract available.
Similar articles
-
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.N Engl J Med. 2016 Apr 28;374(17):1609-20. doi: 10.1056/NEJMoa1514616. Epub 2016 Apr 2. N Engl J Med. 2016. PMID: 27040324 Clinical Trial.
-
Two-year outcomes after transcatheter or surgical aortic-valve replacement.N Engl J Med. 2012 May 3;366(18):1686-95. doi: 10.1056/NEJMoa1200384. Epub 2012 Mar 26. N Engl J Med. 2012. PMID: 22443479 Clinical Trial.
-
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients.N Engl J Med. 2019 May 2;380(18):1695-1705. doi: 10.1056/NEJMoa1814052. Epub 2019 Mar 16. N Engl J Med. 2019. PMID: 30883058 Clinical Trial.
-
Transcatheter aortic valve replacement versus surgery for symptomatic severe aortic stenosis: A reconstructed individual patient data meta-analysis.Catheter Cardiovasc Interv. 2020 Jul;96(1):158-166. doi: 10.1002/ccd.28504. Epub 2019 Sep 30. Catheter Cardiovasc Interv. 2020. PMID: 31566902 Review.
-
Meta-analysis of transfemoral TAVR versus surgical aortic valve replacement.Catheter Cardiovasc Interv. 2018 Mar 1;91(4):806-812. doi: 10.1002/ccd.27357. Epub 2017 Oct 25. Catheter Cardiovasc Interv. 2018. PMID: 29068166 Review.
Cited by
-
Transcatheter Procedure Versus Surgical Interventions for Severe Aortic Stenosis: A Contemporary Evaluation Against Conservative Management.Cureus. 2024 Oct 19;16(10):e71859. doi: 10.7759/cureus.71859. eCollection 2024 Oct. Cureus. 2024. PMID: 39559653 Free PMC article. Review.
-
Transcatheter aortic valve implantation versus surgical aortic valve replacement in Chinese patients with intermediate and high surgical risk for aortic stenosis: a decision analysis on effect, affordability and cost-effectiveness.BMJ Open. 2024 Nov 18;14(11):e082283. doi: 10.1136/bmjopen-2023-082283. BMJ Open. 2024. PMID: 39557556 Free PMC article.
-
Who Lives Longer, the Valve or the Patient? The Dilemma of TAVI Durability and How to Optimize Patient Outcomes.J Clin Med. 2024 Oct 14;13(20):6123. doi: 10.3390/jcm13206123. J Clin Med. 2024. PMID: 39458073 Free PMC article. Review.
-
Prognostic utility of mid-regional pro-adrenomedullin and growth differentiation factor 15 in patients undergoing transfemoral transcatheter aortic valve implantation.Clin Res Cardiol. 2024 Oct 25. doi: 10.1007/s00392-024-02560-w. Online ahead of print. Clin Res Cardiol. 2024. PMID: 39453458
-
The Impact of Frailty and Surgical Risk on Health-Related Quality of Life After TAVI.J Cardiovasc Dev Dis. 2024 Oct 18;11(10):333. doi: 10.3390/jcdd11100333. J Cardiovasc Dev Dis. 2024. PMID: 39452303 Free PMC article. Review.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources